Art. -Nr.: HY-N0135

Tanshinone IIA

(Synonyms: Dan Shen ketone)

36 Cited Publications

Kundenbewertung

Based on 36 publication(s) in Google Scholar

Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of VEGF/VEGFR2.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.78%
CAS. Nr.: 568-72-9
Formel: C₁₉H₁₈O₃
Molecular Weight:294.34

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years

* The compound is unstable in solutions, freshly prepared is recommended.

Tanshinone IIA Chemical Structure

CAS. Nr.: 568-72-9

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (36)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

VEGF/VEGFR2^[1]

Alle VEGFR Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	2.2 μM Compound: 2a	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
A549	IC₅₀	53.2 μM Compound: Tan-IIA	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30398868]
A549	IC₅₀	6.68 μM Compound: 7; TSA	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by cell titer glo luminescent assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by cell titer glo luminescent assay	[PMID: 35640078]
AGS	IC₅₀	10 μM Compound: 7, tanshinone iia	Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
AGS	IC₅₀	6.8 μM Compound: 7, tanshinone iia	Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
AGS	IC₅₀	7.53 μM Compound: 7, tanshinone iia	Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
BGC-823	IC₅₀	2.8 μM Compound: 10	Anticancer activity against human BGC-823 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human BGC-823 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
CWR22R	IC₅₀	6.7 μM Compound: TS-IIA	Cytotoxicity against human 22Rv1 cells incubated for 72 hrs by MTT assay Cytotoxicity against human 22Rv1 cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
HeLa	IC₅₀	193.2 μM Compound: Tan-IIA	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30398868]
HeLa	IC₅₀	3.47 μM Compound: 2a	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
Hep 3B2	IC₅₀	>50 μM Compound: 7, tanshinone iia	Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
Hep 3B2	IC₅₀	>50 μM Compound: 7, tanshinone iia	Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
Hep 3B2	IC₅₀	6.18 μM Compound: 7, tanshinone iia	Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
HepG2	IC₅₀	23.85 μM Compound: TSA	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 33601313]
HepG2	IC₅₀	23.9 μM Compound: Tanshinone IIA	Antiproliferative activity against human HepG2 cells Antiproliferative activity against human HepG2 cells	[PMID: 33421712]
HepG2	IC₅₀	4.91 μM Compound: 2a	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
HepG2	IC₅₀	65.7 μM Compound: Tan-IIA	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30398868]
K562	IC₅₀	4.6 μM Compound: TSA	Cytotoxicity against human K562 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 38889607]
L02	IC₅₀	65.29 μM Compound: TSA	Antiproliferative activity against human L02 cells by MTT assay Antiproliferative activity against human L02 cells by MTT assay	[PMID: 33601313]
L02	IC₅₀	78.5 μM Compound: Tan-IIA	Antiproliferative activity against human L02 cells after 72 hrs by MTT assay Antiproliferative activity against human L02 cells after 72 hrs by MTT assay	[PMID: 30398868]
LNCaP	IC₅₀	0.5 μM Compound: TS-IIA	Cytotoxicity against human LNCAP cells incubated for 72 hrs by MTT assay Cytotoxicity against human LNCAP cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
LNCaP C4-2B	IC₅₀	0.4 μM Compound: TS-IIA	Cytotoxicity against human C4-2B cells incubated for 72 hrs by MTT assay Cytotoxicity against human C4-2B cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
MCF7	EC₅₀	0.9 μM Compound: Tan II-A	Cytotoxicity against telomerase positive human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against telomerase positive human MCF7 cells after 96 hrs by SRB assay	[PMID: 22044621]
MCF7	ED₅₀	0.38 μg/mL Compound: Tanshinone IIA	Dose required for reduction in cell growth of human breast cancer MCF-7 cell line Dose required for reduction in cell growth of human breast cancer MCF-7 cell line	[PMID: 15509181]
MCF7	IC₅₀	>5 μM Compound: 2a	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
MCF7	IC₅₀	7.7935 μM Compound: 2	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 33751939]
MDA-MB-231	ED₅₀	0.7 μg/mL Compound: Tanshinone IIA	Dose required for reduction in cell growth of human breast cancer MDA-MB-231 cell line Dose required for reduction in cell growth of human breast cancer MDA-MB-231 cell line	[PMID: 15509181]
MDA-MB-231	IC₅₀	115.9 μM Compound: Tan-IIA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 30398868]
MDA-MB-231	IC₅₀	7.695 μM Compound: 2	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 33751939]
MGC-803	IC₅₀	>5 μM Compound: 2a	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]
MIA PaCa-2	IC₅₀	1.9 μM Compound: 13	Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay	[PMID: 21775156]
NCI-N87	IC₅₀	3.1 μM Compound: 10	Anticancer activity against human NCI-N87 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human NCI-N87 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
PC-3	EC₅₀	1.2 μM Compound: Tan II-A	Cytotoxicity against telomerase positive human PC3 cells after 96 hrs by SRB assay Cytotoxicity against telomerase positive human PC3 cells after 96 hrs by SRB assay	[PMID: 22044621]
PC-3	IC₅₀	3.2 μM Compound: TSA	Cytotoxicity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 38889607]
PC-3	IC₅₀	3.3 μM Compound: TS-IIA	Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 22175694]
RAW264.7	IC₅₀	18.17 μM Compound: 1	Inhibition of TRAP activity in RANKL-induced osteoclastogenesis in RAW 264.7 cells Inhibition of TRAP activity in RANKL-induced osteoclastogenesis in RAW 264.7 cells	[PMID: 16872829]
SAOS-2	EC₅₀	>20 μM Compound: Tan II-A	Cytotoxicity against telomerase negative human Saos2 cells after 96 hrs by SRB assay Cytotoxicity against telomerase negative human Saos2 cells after 96 hrs by SRB assay	[PMID: 22044621]
SGC-7901	IC₅₀	250 μM Compound: 10	Anticancer activity against human SGC-7901 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SGC-7901 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 36332549]
U-937	IC₅₀	>5 μM Compound: 2a	Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human U-937 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34333396]

In Vitro

The anti-tumor effect of Tanshinone IIA includes inhibiting tumor cell proliferation, disturbing tumor cell cycle, promoting tumor cell apoptosis, and inhibiting tumor cell invasion and transfer. Tanshinone IIA has anti-proliferative effects on A549 cells: the IC₅₀ of Tanshinone IIA after 24, 48 and 72 h are 145.3, 30.95 and 11.49 μM, respectively. The CCK-8 assay is used to evaluate the proliferative activity of A549 cells treated with Tanshinone IIA (2.5-80 μM) for 24, 48 and 72 h, respectively. The CCK-8 results show that Tanshinone IIA can significantly inhibit A549 cell proliferation in a dose- and time-dependent manner. Obvious apoptosis and cell growth inhibition of A549 cells are observed after drug treatment for 48 h (concentrations used are approximately IC₅₀ values: Tanshinone IIA 31 μM on A549). Western blotting finds that 48 h exposures to Tanshinone IIA (31 μM) in A549 cells, downregulates expression of VEGF and VEGFR2 protein in both drug treatment groups vs. vehicle^[1].
Tanshinone IIA, one of the most abundant constituents of the root of Salvia miltiorrhiza, protects rat myocardium-derived H9C2 cells against apoptosis. Treatment of H9C2 cells with Tanshinone IIA inhibits angiotensin II-induced apoptosis by downregulating the expression of PTEN (phosphatase and tensin homolog), a tumor suppressor that plays a critical role in apoptosis. Tanshinone IIA inhibits angiotensin II (AngII)-induced apoptosis by downregulating the expression of phosphatase and tensin homolog (PTEN)^[2].
Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tanshinone IIA (10 or 20 mg/kg; p.o) significantly reverses scopolamine-induced cognitive impairments^[1].
Tanshinone IIA (2, 4, 8 mg/kg; i.p.) mediated protective effects on the STZ-induced diabetic nephropathy may be associates with the reduced endoplasmic reticulum stress via attenuating PERK signaling activities^[2].
Tanshinone IIA (3 and 12 mg/kg; i.p.) significantly inhibits the growth of ectopic endometrium^[3].
Tanshinone IIA has been used interchangeably with Tanshinone IIA sulfonate sodium (HY-N1370) in some studies, but there are differences in water solubility, chemical structure, pharmacological activity and pharmacokinetics. When administering to animals, please prepare a solid dispersion or choose to use the sulfonate form of Tanshinone IIA sulfonate sodium (HY-N1370) with better water solubility^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male ICR mice (25–30 g)^[4]
Dosage:

10 or 20 mg/kg
Administration:

P.o.
Result:

Significantly reversed scopolamine-induced cognitive impairments.

Animal Model:

STZ-treated rats^[5]
Dosage:

2, 4, 8 mg/kg
Administration:

I.p.
Result:

Decreased the expression levels of transforming growth factor-beta1, TSP-1, Grp78 and CHOP and attenuated the increase in the protein levels of p-PERK, p-elf2α and ATF-4 from the renal tissues of diabetic rats.

Animal Model:

Female Sprague-Dawley rats (180 -200g)^[6]
Dosage:

3 and 12 mg/kg
Administration:

I.p.
Result:

Significantly inhibited the growth of ectopic endometrium.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 568-72-9
Appearance Solid
Molecular Weight 294.34
Formel C₁₉H₁₈O₃
Color Orange to red
SMILES

O=C(C1=C2C=CC3=C1CCCC3(C)C)C(C4=C2OC=C4C)=O
Synonyms

Dan Shen ketone
Structure Classification
- Terpenoids
- Diterpenoids
- Quinones
- Naphthalene Quinones
Initial Source
- Plants
- Labiatae
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years

* The compound is unstable in solutions, freshly prepared is recommended.

Publications (36)

All WBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Phytomedicine

Tanshinone IIA attenuates sepsis-induced lung injury by reducing VEGFR2/PI3K/AKT-driven mitochondrial disruption dependent apoptosis. [Abstract]

2025 Jun 14:145:156957. PMID: 40544732
Phytomedicine

Tanshinone IIA promotes ferroptosis in cutaneous melanoma via STAT1-mediated upregulation of PTGS2 expression. [Abstract]

2025 Apr 5:141:156702. PMID: 40222167
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Sci Total Environ

CD36-mediated ROS/PI3K/AKT signaling pathway exacerbates cognitive impairment in APP/PS1 mice after noise exposure. [Abstract]

2024 Sep 2:175879. PMID: 39233068
J Transl Med

Tanshinone IIA ameliorates Aβ transendothelial transportation through SIRT1-mediated endoplasmic reticulum stress. [Abstract]

2023 Jan 20;21(1):34. PMID: 36670462

Tanshinone IIA purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Jan 20;21(1):34. [Abstract]

Tanshinone IIA (Tan IIA; 24 h) significantly decreases the cell viability when concentration reaches to 50 µM in bEnd0.3 cells.
Cell Rep

Activation status of astrocytes drives the MS/NMOSD therapeutic paradox: Insights from IFNAR1 signaling. [Abstract]

2026 Feb 2;45(2):116913. PMID: 41632569
Phytother Res

Tanshinone IIA improves contextual fear- and anxiety-like behaviors in mice via the CREB/BDNF/TrkB signaling pathway. [Abstract]

2022 Oct;36(10):3932-3948. PMID: 35801985
Cancer Cell Int

Tanshinone IIA regulates human AML cell proliferation, cell cycle, and apoptosis through miR-497-5p/AKT3 axis. [Abstract]

2020 Aug 7;20:379. PMID: 32782437
Biochem Pharmacol

Renin inhibition improved muscular function by alleviating insulin resistance and AGEs/RAGE signaling in skeletal muscle associated with high glucose: Exploration of renin inhibitor tanshinone IIA. [Abstract]

2025 Dec 13:245:117635. PMID: 41391695
Chem Biol Interact

Tanshinone IIA attenuates silica-induced pulmonary fibrosis via Nrf2-mediated inhibition of EMT and TGF-β1/Smad signaling. [Abstract]

2020 Mar 1;319:109024. PMID: 32097614
Int J Mol Sci

The Activation of p300 Enhances the Sensitivity of Pituitary Adenomas to Dopamine Agonist Treatment by Regulating the Transcription of DRD2. [Abstract]

2024 Nov 21;25(23):12483. PMID: 39684198
Pharm Biol

Tanshinone IIA reduces tubulointerstitial fibrosis by suppressing GSDMD-mediated pyroptosis. [Abstract]

2025 Dec;63(1):364-373. PMID: 40331369
Eur J Pharmacol

Tanshinone ⅡA inhibits VSMC inflammation and proliferation in vivo and in vitro by downregulating miR-712-5p expression. [Abstract]

2020 Aug 5;880:173140. PMID: 32387370

Tanshinone IIA purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2020 Aug 5;880:173140. [Abstract]

Phospho-p65 (p-p65), p65, IL-1β, IL-6, TNF-α, and KLF4 expression in unligated, ligated and ligated + Tan IIA-treated carotid arteries is determined by Western blotting days 21 after carotid artery ligation.
Mater Today Commun

2026 Feb 3.
ACS Omega

Investigating the Mechanism of the Fuzheng Huayu Formula in Treating Cirrhosis through Network Pharmacology, Molecular Docking, and Experimental Verification. [Abstract]

2025 Apr 29;10(18):19019-19032. PMID: 40385224
Mediators Inflamm

Tanshinone IIA Alleviates Traumatic Brain Injury by Reducing Ischemia‒Reperfusion via the miR-124-5p/FoxO1 Axis. [Abstract]

2024 Mar 21:2024:7459054. PMID: 38549714
J Integr Med

Tanshinone IIA prevents acute lung injury by regulating macrophage polarization. [Abstract]

2022 May;20(3):274-280. PMID: 35181255
Sci Rep

Dynamic change of estrogen and progesterone metabolites in human urine during pregnancy. [Abstract]

2025 Mar 11;15(1):8409. PMID: 40069295
Regen Ther

Tanshinone IIA suppresses fibro-adipogenic progenitor differentiation and attenuates fat infiltration in rotator cuff injury via Wnt/β-catenin pathway. [Abstract]

2025 Aug 13:30:584-594. PMID: 40837862
Microb Pathog

Natural small molecule compounds targeting Wnt signaling pathway inhibit HPV infection. [Abstract]

2024 Sep 21:106960. PMID: 39313132
Eur J Med Res

Tanshinone IIA induces ferroptosis in colorectal cancer cells through the suppression of SLC7A11 expression via the PI3K/AKT/mTOR pathway. [Abstract]

2025 Jul 5;30(1):576. PMID: 40618168
Acta Biochim Biophys Sin (Shanghai)

Tanshinone IIA potentiates the therapeutic efficacy of glucocorticoids in lipopolysaccharide-treated HEI-OC1 cells through modulation of the FOXP3/Nrf2 signaling pathway. [Abstract]

2024 Nov 1;57(5):727-737. PMID: 39483046
Stem Cells Int

Tanshinone ΙΙ A-Incubated Mesenchymal Stem Cells Inhibit Lipopolysaccharide-Induced Inflammation of N9 Cells through TREM2 Signaling Pathway. [Abstract]

2022 Mar 4:2022:9977610. PMID: 35283996
Environ Toxicol

Tanshinone IIA inhibits gastric cancer cell stemness through inducing ferroptosis. [Abstract]

2022 Feb;37(2):192-200. PMID: 34661962
Pharmacology

Tanshinone IIA Ameliorates Inflammation Response in Osteoarthritis via Inhibition of miR-155/FOXO3 Axis. [Abstract]

2021;106(1-2):20-28. PMID: 33395681
J Pharm Pharmacol

Tanshinone IIA effects on ovarian cancer cell line. [Abstract]

2018 Oct;70(10):1369-1377. PMID: 29943422

Tanshinone IIA purchased from MedChemExpress. Usage Cited in: J Pharm Pharmacol. 2018 Oct;70(10):1369-1377. [Abstract]

Tanshinone IIA induces TOV-21G apoptosis. Western blotting is performed with anti-Cleaved caspase 3 or anti-cleaved poly ADP-ribose polymerase (PARP) antibodies. Tubulin is loaded as the loading control.
Life Sci Alliance

Tanshinone functions as a coenzyme that confers gain of function of NQO1 to suppress ferroptosis. [Abstract]

2022 Nov 1;6(1):e202201667. PMID: 36319062
Clin Exp Pharmacol Physiol

Combination of Tanshinone IIA and Matrine Alleviates Lipopolysaccharide-Induced Acute Lung Injury by Supressing Ferroptosis via Nrf2/HO-1 Pathway Activation. [Abstract]

2025 Nov;52(11):e70072. PMID: 41063422
Biomed Res Int

Radix Salvia miltiorrhiza for Ankylosing Spondylitis: Determining Potential Inflammatory Molecular Targets and Mechanism Using Network Pharmacology. [Abstract]

2022 Sep 13;2022:3816258. PMID: 36147634
Exp Ther Med

Inhibition of cell survival and invasion by Tanshinone IIA via FTH1: A key therapeutic target and biomarker in head and neck squamous cell carcinoma. [Abstract]

2022 Jun 16;24(2):521. PMID: 35837069
Eur J Histochem

Tanshinone IIA attenuates hepatic stellate cell activation, oxidative stress, and liver fibrosis by inhibiting YAP signaling. [Abstract]

2025 Jun 17;69(3). PMID: 40525818
Eur J Integr Med

2025 Mar 22.
Biochem Genet

Tanshinone IIA Inhibits Microglial Activation and Inflammation and Relieves Cerebral Ischemia‒Reperfusion Injury Through TGM2/PANX1. [Abstract]

2025 Dec 6. PMID: 41351813
Res Sq

2025 May 05.
Research Square Preprint

2023 Jun 29.
Evid Based Complement Alternat Med

Tanshinone IIa Induces Autophagy and Apoptosis via PI3K/Akt/mTOR Axis in Acute Promyelocytic Leukemia NB4 Cells. [Abstract]

2021 Oct 15:2021:3372403. PMID: 34691211

Lösungsmittel & Löslichkeit

In Vitro:

DMF : 5 mg/mL (16.99 mM; ultrasonic and warming and heat to 60°C)

Ethanol : 1 mg/mL (3.40 mM; ultrasonic and warming and heat to 60°C)

DMSO : 1 mg/mL (3.40 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3974 mL

16.9872 mL

33.9743 mL

5 mM

0.6795 mL

3.3974 mL

6.7949 mL

10 mM

0.3397 mL

1.6987 mL

3.3974 mL

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 0.1 mg/mL (0.34 mM); Clear solution

This protocol yields a clear solution of ≥ 0.1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (1.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/0.1% Tween-80 in Saline water

Solubility: 1 mg/mL (3.40 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Xie J, et al. The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line. Acta Pharm Sin B. 2015 Nov;5(6):554-63. [Content Brief]

[2]. Zhang Z, et al. Tanshinone IIA inhibits apoptosis in the myocardium by inducing microRNA-152-3p expression and thereby downregulating PTEN. Am J Transl Res. 2016 Jul 15;8(7):3124-32. [Content Brief]

[3]. Su CC, et al. Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo. Oncol Rep. 2016 Aug;36(2):1173-9. [Content Brief]

[4]. Zhongyan Zhou, et al. Sodium tanshinone IIA sulfonate: a review of pharmacological activity and pharmacokinetics. Biomedicine & Pharmacotherapy 118 (2019): 109362. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO / DMF	1 mM	3.3974 mL	16.9872 mL	33.9743 mL	84.9358 mL
DMF	5 mM	0.6795 mL	3.3974 mL	6.7949 mL	16.9872 mL
	10 mM	0.3397 mL	1.6987 mL	3.3974 mL	8.4936 mL
	15 mM	0.2265 mL	1.1325 mL	2.2650 mL	5.6624 mL

Keywords

Tanshinone IIA

36 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Tanshinone IIA

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) Tanshinone IIA

Alle VEGFR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (36)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Tanshinone IIA

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) Tanshinone IIA

Alle VEGFR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (36)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Tanshinone IIA Related Classifications

Art. -Nr.: HY-N0135